An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Authors
Category Systematic review
JournalBlood
Year 2019
This article has no abstract
Epistemonikos ID: 093d38e360cb7bc5bf0b737cc94cd9d1a1d72899
First added on: Feb 11, 2025